Business Context and Reporting Period
Company: Church & Dwight Co., Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 26, 2009
Business Overview: The Company operates in three reportable segments: Consumer Domestic (household and personal care products), Consumer International (primarily personal care products), and Specialty Products Division (specialty chemical products). The reporting period includes the impact of the July 2008 acquisition of Del Pharmaceuticals (Orajel brand) and ongoing construction of a new manufacturing facility in York County, Pennsylvania.
Key Financial Metrics
| Metric | Three Months Ended June 26, 2009 |
Six Months Ended June 26, 2009 |
|---|---|---|
| Net Sales | $623.1 million | $1,204.0 million |
| Gross Profit | $281.6 million | $530.9 million |
| Gross Margin | 45.2% | 44.1% |
| Operating Income | $99.0 million | $203.7 million |
| Net Income (Attributable to C&D) | $58.2 million | $120.7 million |
| Diluted EPS | $0.81 | $1.69 |
| Cash and Cash Equivalents | $357.0 million | $357.0 million (Balance Sheet) |
| Operating Cash Flow | N/A | $194.8 million |
| Total Debt | $849.5 million | $849.5 million |
| Net Debt | $492.5 million | $492.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.9% in the quarter and 5.0% for the six months compared to the prior year. Growth was driven by the Orajel acquisition, higher unit volumes, improved sales mix, and price increases, partially offset by unfavorable foreign exchange rates (approx. 3.8% impact in Q2).
- Margin Expansion: Gross margin improved by 440 basis points in Q2 (to 45.2%) and 340 basis points for the six months (to 44.1%). Drivers included lower commodity costs, the Orajel acquisition, and cost reduction programs, partially offset by accelerated depreciation charges related to the North Brunswick facility closure.
- Profitability: Net income increased 27.1% in Q2 and 18.4% for the six months. Operating income rose due to higher sales and margins, despite increased marketing expenses (up 18.3% in Q2) and SG&A expenses.
- Segment Performance:
- Consumer Domestic: Sales up 13.7% in Q2, driven by volume and price increases in laundry and personal care products.
- Consumer International: Sales down 16.0% in Q2, primarily due to unfavorable foreign exchange rates (18% impact) and the divestiture of the Spanish subsidiary.
- Specialty Products: Sales down 13.4% in Q2 due to lower volumes in the animal nutrition business and foreign exchange headwinds.
Outlook, Risks, and Unusual Items
- Capital Expenditures: The Company is constructing a new laundry detergent plant in York County, PA, with total expected costs of approximately $150 million. Approximately $45 million was spent in the first six months of 2009, with an additional $54 million anticipated for the remainder of the year.
- Facility Closure: The Company is closing its North Brunswick, NJ facility. Total estimated costs include $11 million in cash exit costs and $24.6 million in non-cash accelerated depreciation. $9.0 million of depreciation was recorded in the first six months of 2009.
- Dividend Increase: On July 29, 2009, the Board declared an increase in the quarterly dividend from $0.09 to $0.14 per share.
- Liquidity: The Company maintains strong liquidity with $357 million in cash and significant available borrowing capacity. It is currently compliant with financial covenants (Leverage ratio 1.8x vs. 3.25x max; Interest coverage 11.4x vs. 3.0x min).
- Legal Proceedings: The Company is involved in patent litigation with Abbott Laboratories regarding pregnancy diagnostic test kits. A judgment of over $38 million (including interest) was awarded to Church & Dwight, but Abbott has filed an appeal.
- Risk Factors: Risks include economic conditions affecting consumer demand, raw material price volatility, foreign exchange fluctuations, and regulatory changes regarding product labeling (specifically N-9 lubricated condoms).
Investor Verification Checklist
- Acquisition Integration: Verify the ongoing contribution of the Orajel acquisition to sales and margins versus the amortization costs of acquired intangibles.
- Capital Project Timeline: Monitor the completion date and cost overruns for the new York County, PA facility and the associated transition costs.
- Foreign Exchange Sensitivity: Assess the impact of currency fluctuations on the Consumer International segment, which saw significant sales declines due to FX rates.
- Legal Contingency: Track the status of the Abbott Laboratories appeal regarding the $38 million judgment.
- Debt Structure: Review the terms of the interest rate hedges (collars and swaps) and the impact of rising interest rates on the floating-rate portion of the debt.